Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Pingzheng Mo¹,*, Yuanyuan Xing²,*, Yu Xiao²,*, Liping Deng¹,*, Qiu Zhao³, Hongling Wang³, Yong Xiong¹, Zhenshun Cheng⁴, Shicheng Gao¹, Ke Liang¹, Mingqi Luo¹, Tielong Chen¹, Shihui Song¹, Zhiyong Ma¹, Xiaoping Chen¹, Ruiying Zheng¹, Qian Cao¹, Fan Wang³,*, Yongxi Zhang¹,*

¹Department of Infectious Disease, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China
²Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China
³Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China
⁴Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China

* Pingzheng Mo, Yuanyuan Xing, Yu Xiao and Liping Deng contributed equally.

# Corresponding author: Fan Wang and Yongxi Zhang, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China. E-mail: fanndywang@foxmail.com; znact1936@126.com
Brief summary

Nearly 50% patients of novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) could not reach obvious clinical and radiological remission within 10 days after hospitalization. These refractory COVID-19 patients showed an obvious difference with the general patients in clinical characteristics.
Abstract

**Background:** Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. This study aimed to clarify the characteristics of patients with refractory COVID-19.

**Methods:** In this retrospective single-center study, we included 155 consecutive patients with confirmed COVID-19 in Zhongnan Hospital of Wuhan University from January 1st to February 5th. The cases were divided into general and refractory COVID-19 groups according to the clinical efficacy after hospitalization, and the difference between groups were compared.

**Results:** Compared with general COVID-19 patients (45.2%), refractory patients had an older age, male sex, more underlying comorbidities, lower incidence of fever, higher levels of maximum temperature among fever cases, higher incidence of breath shortness and anorexia, severer disease assessment on admission, high levels of neutrophil, aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and C-reactive protein, lower levels of platelets and albumin, and higher incidence of bilateral pneumonia and pleural effusion (P<0.05). Refractory COVID-19 patients were more likely to receive oxygen, mechanical ventilation, expectorant, and adjunctive treatment including corticosteroid, antiviral drugs and immune enhancer (P<0.05). After adjustment, those with refractory COVID-19 were also more likely to have a male sex and manifestations of anorexia and fever on admission, and receive oxygen, expectorant and adjunctive agents (P<0.05) when considering the factors of disease severity on admission, mechanical ventilation, and ICU transfer.

**Conclusion:** Nearly 50% COVID-19 patients could not reach obvious clinical and radiological remission within 10 days after hospitalization. The patients with male sex, anorexia and no fever on admission predicted poor efficacy.

**Key words:** COVID-19; SARS-CoV-2; clinical efficacy; predictors
Introduction

Since December 2019, an outbreak of pneumonia of unknown cause occurred in Wuhan, and rapidly spread throughout China [1-3]. The pathogen was confirmed to be a distinct clade from the β-coronaviruses associated with the Middle East syndrome (MERS) and severe acute respiratory syndrome (SARS) [4, 5]. The novel virus was officially named SARS-CoV-2, with the disease termed COVID-19 [6]. Epidemiological data demonstrated person-to-person transmission in hospital and family settings [7, 8]. The high infectivity of COVID-19 resulted in a rapid increase of new cases and a worldwide outbreak [9, 10].

Up to now, there found no antiviral drug with definite effects, and the main therapeutic strategy focused on symptomatic support. Partial patients showed poor treatment efficacy after hospitalization, and developed severe pneumonia, pulmonary oedema, acute respiratory distress syndrome (ARDS) or multiple organ failure. At present, information regarding the clinical characteristics of refractory COVID-19 was scarce. In this study, we aimed to clarify the characteristics of patients with refractory COVID-19.
METHODS

Study design and participants

This retrospective study was approved by the ethics committee of Zhongnan Hospital of Wuhan University (No. 2020011). All consecutive patients with confirmed COVID-19 admitted to Zhongnan Hospital of Wuhan University from January 1st to February 5th were enrolled. Written or oral informed consent was obtained from patients.

Definitions

COVID-19 was confirmed by detecting SARS-CoV-2 RNA in throat swab samples using a virus nucleic acid detection kit according to the manufacturer’s protocol (Shanghai BioGerm Medical Biotechnology Co., Ltd.). For hospitalized patients, general COVID-19 was defined according to following criteria: (i) obvious alleviation of respiratory symptoms (e.g. cough, chest distress and breath shortness) after treatment; (ii) maintenance of normal body temperature for ≥3 days without the use of corticosteroid or antipyretics; (iii) improvement in radiological abnormalities on chest CT or X-ray after treatment; (iv) a hospital stay of ≤10 days. Otherwise, it was classified as refractory COVID-19. Figure 1 showed the chest-imaging dynamics of a refractory COVID-19 patient.

In severity assessment on admission, serious illness was defined if satisfying at least one of the following items: (i) breathing rate ≥30/min; (ii) pulse oximeter oxygen saturation (SpO₂) ≤93% at rest; (iii) ration of partial pressure of arterial oxygen (PaO₂) to fraction of inspired oxygen (FiO₂) ≤300mmHg (1mmHg=0.133kPa). Critical illness was defined if satisfying at least one of the following items: (i) respiratory failure occurred and received mechanical ventilation; (ii) shock; (iii)
combined with failure of other organs and received care in the intensive care unit (ICU).

Data collection

A COVID-19 case report form was designed to document primary data regarding demographic, clinical, laboratory, radiological and therapeutic characteristics from electronic medical records. The following information was extracted from each patient: age, gender, medical history, COVID-19-related exposure history, symptoms, signs, severity assessment on admission, laboratory findings, chest CT or X-ray findings, and treatment like antivirus, corticosteroid and respiratory support.

Statistical analysis

Categorical data were described as percentages, and continuous data as median with interquartile range (IQR). Nonparametric comparative test for continuous data and $\chi^2$ test for categorical data were used to compare variables between groups. $P<0.05$ was considered statistically significant. The variables identified by univariate analysis ($P<0.05$) were put into the multivariate analysis, in which these variables were adjusted by three main factors (disease severity on admission, mechanical ventilation, and ICU transfer). All statistical analyses were performed using SPSS Statistics version 21.0 software.
RESULTS

Baseline characteristics

155 patients with COVID-19 pneumonia were included in this study (Table 1). The median age was 54 years (IQR: 42~66), and 86 patients (55.5%) were male. 6 patients (3.9%) were current smokers, and 37 (23.9%) had a history of exposure to source transmission (Huanan seafood market or infected individuals). 71 patients (45.8%) had at least one comorbidity, including hypertension (23.9%), diabetes (9.7%) and cardiovascular diseases (9.7%). Fever (81.3%), fatigue (73.2%), cough (62.6%), and myalgia/arthralgia (61.0%) were the most common symptoms, while digestive symptoms were scare. On admission, 55 (35.5%) and 37 (23.9%) patients were categorized into serious and critical illness respectively.

After hospitalization, 70 patients (45.2%) reached obvious clinical and radiological remission within 10 days. Compared with these general COVID-19 patients, refractory patients were significantly older (P<0.001) and male dominated (P=0.011). Meanwhile, refractory patients have more underlying comorbidities (P<0.001) including diabetes (P=0.039), cardiovascular diseases (P=0.002) and cerebrovascular diseases (P=0.039), lower incidence of fever (P=0.012), higher levels of maximum temperature among fever cases (P=0.005), and higher incidence of breath shortness (P=0.009) and anorexia (P=0.005), and severer disease assessment on admission (P<0.001).

Laboratory and radiological findings

On admission, the majority of patients had lymphopenia and abnormalities of neutrophils, platelets, aspartate aminotransferase (AST), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and inflammatory biomarkers as described in
Table 2. According to CT or X-ray findings, 143 patients (92.3%) showed bilateral pneumonia, and pleural effusion occurred in 16 patients (10.3%).

Compared with general patients, refractory patients had a higher level of neutrophils ($P=0.017$), AST ($P=0.004$), LDH ($P=0.017$) and C-reactive protein (CRP, $P=0.001$), and lower level of platelets ($P=0.049$) and albumin ($P=0.001$). Moreover, refractory patients had a higher incidence of bilateral pneumonia ($P=0.031$) and pleural effusion ($P=0.006$).

Treatment

Of the 155 patients, 102 patients (65.8%) received oxygen, and 36 (23.2%) with mechanical ventilation (Table 3). 87 patients (56.1%) received expectorant, and 79 (51%) received intravenous corticosteroid. 45 patients (29%) received special antiviral treatment (arbidol, 20.0%; lopinavir and ritonavir, 17.4%; interferon inhalation, 19.4%). 14 patients (9%) received immune enhancing treatment (thymalfasin, 7.1%; immunoglobulin, 5.8%). The frequency of combined administration of adjunctive agents was 18.7% for corticosteroid plus antiviral drugs, 8.4% for corticosteroid plus immune enhancer, 6.5% for antiviral drugs plus immune enhancer, and 5.8% for the all.

Compared with general patients, refractory patients were more likely to receive oxygen ($P<0.001$), mechanical ventilation ($P<0.001$), expectorant ($P<0.001$), corticosteroid ($P<0.001$), lopinavir and ritonavir ($P=0.008$), and immune enhancer ($P=0.015$) especially thymalfasin ($P=0.005$).
Multivariate analysis of factors associated with COVID-19 refractoriness

24 significant factors in univariate analysis were put into the multivariate analysis to identify reliable predictive factor for COVID-19 refractoriness (Table 4). The results indicated male sex ($P=0.047; \text{OR: } 2.206, \text{95\% CI: } 1.012-4.809$) and anorexia on admission ($P=0.030; \text{OR: } 3.921, \text{95\% CI: } 1.144-13.443$) as the risk factors for disease refractoriness, and fever on admission as the protective factor ($P=0.039; \text{OR: } 0.331, \text{95\% CI: } 0.116-0.945$). Moreover, refractory patients were more likely to receive oxygen ($P=0.020; \text{OR: } 3.065, \text{95\% CI: } 1.189-7.897$), expectorant ($P=0.016; \text{OR: } 2.688, \text{95\% CI: } 1.204-6.003$), corticosteroid ($P=0.042; \text{OR: } 2.232, \text{95\% CI: } 1.030-4.838$), lopinavir and ritonavir ($P<0.001; \text{OR: } 13.975, \text{95\% CI: } 3.274-59.655$), and immune enhancer ($P=0.009; \text{OR: } 8.959, \text{95\% CI: } 1.724-46.564$).

DISCUSSION

Since the outbreak of COVID-19, the number of patients had increased dramatically, and some patients had died from the disease. It had been reported that the median hospital stay of patients with COVID-19 pneumonia was 10 days [11]. In our study, the median hospital stay for dead cases (n=22) was 10.5 days (IQR: 8–16), and 10 days (IQR: 7–15) for the recovered cases. After 10 days or longer treatment, some patients had an exacerbation in clinical symptoms or radiological findings. Therefore, clinicians should identify refractory and critical illness timely and provide early interventions, which was conducive to shorten the course of disease, prevent disease progression and reduce mortality. Up to now, large-scale analyses of clinical characteristics of refractory COVID-19 had been scarce. In this study, 155 COVID-19 patients were divided into general and refractory groups. We compared the clinical features, imaging manifestations, serological examination and the treatment between two groups.
We found that despite of a similar proportion of male and female patients in COVID-19, male patients had a higher incidence of disease refractoriness. The mean age of refractory patients was significantly older than that of general patients. In addition, 49% of patients with COVID-19 had other chronic diseases, which was consistent with recent reports [11, 12]. Thus, it could be seen that the elderly male patients with certain chronic diseases were more difficult to treat, resulting in a long hospital stay and slow recovery.

COVID-19 was similar to SARS and MERS in some clinical manifestations. In COVID-19 patients, fever, cough and myalgia were the most common symptoms, followed by chest distress and shortness of breath. However, upper respiratory tract symptoms (eg. nasal congestion, nasal discharge and sore throat) and gastrointestinal symptoms (eg. abdominal pain and diarrhea) were relatively rare. Fever occurred in 98–100% of SARS or MERS patients, compared to 81.3% COVID-19 patients in this study [13, 14]. 18.7% of patients presented no fever on admission, suggesting that the absence of fever could not rule out the possibility of COVID-19. If fever was used to trigger screening/testing for COVID-19, a substantial number of patients without fever might be missed. It was worth noting that only 74.1% of refractory patients presented fever, and it was significantly lower than general patients. These findings suggested that patients with a slow or meager response to the virus were more likely to have a severe disease.

In radiological findings, all patients in this study had abnormal chest CT results. The lung lesions were mainly manifested as ground glass-like shadows and patchy shadows on CT. Refractory patients had a higher incidence of pleural effusion than general patients, suggesting a more obviously inflammatory response in the lung. These findings also indicated that SARS-CoV-2 mainly targeted the cells in the lower respiratory tract.
In laboratory findings, 73.5% COVID-19 patients had lymphopenia, but no significant difference was detected between the groups. In refractory patients, blood LDH and CRP levels increased significantly. LDH was an inflammatory predictor in many pulmonary diseases, such as obstructive disease, microbial pulmonary disease, and interstitial pulmonary disease [15, 16]. CRP was a widely used biochemical indicator for inflammation, reflecting the acute severe systemic inflammatory response caused by viral infection. In a recent study, COVID-19 patients treated in the ICU had a higher level of LDH and CRP than those not treated in the ICU [11]. These indicated that SARS-CoV-2 might mainly act on lymphocytes, and involve in the cell-mediated immunity and cytokine storms. The immunological mechanism needed further study.

Currently, there are no data from any of the published experience that any of the antiviral agents used in this outbreak have had a significant impact on the outcome. Most patients recovered despite receiving antiviral and anti-inflammatory treatments, but it was more due to the supportive care with oxygen, fluid management, mechanical ventilation as needed, pressor support, and intensive care management. In this study, refractory patient were more likely to receive oxygen therapy, ventilator support and a variety of adjunctive agents, indicating the treatment insensitivity for these patients and resulting in a delay of the clinical course.

There were some limitations in this study. First, selection bias might occur for this retrospective study, and further prospective studies were needed. Second, this study was based on a single center, and a large-scale nationwide study was needed.

In conclusion, nearly 50% COVID-19 patients could not reach obvious clinical and radiological remission within 10 days after hospitalization. The patients with anorexia and no fever on admission predicted poor efficacy.
Acknowledgement

We thank the patients, the nurses and physicians who provided care for the patients, and the investigators at Zhongnan Hospital of Wuhan University.

**Funding:** This project was supported by the Program of Excellent Doctoral (Postdoctoral) of Zhongnan Hospital of Wuhan University (Grant No. ZNYB2019003).

**Conflict of Interest:** None.
References

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. LANCET 2020-01-24.

2. Li Q, Guan X, Wu P, Wang X, Zhou L. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine 2020.

3. Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. J MED VIROL 2020-01-16.

4. Malik YS, Sircar S, Bhat S, et al. Emerging novel Coronavirus (2019-nCoV) - Current scenario, evolutionary perspective based on genome analysis and recent developments., 2020.

5. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding., 2020.

6. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J AUTOIMMUN 2020-02-26:102433.

7. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. LANCET 2020-01-24.

8. Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin., 2020.

9. Lillie PJ, Samson A, Li A, et al. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. J Infect 2020-02-28.
10. Spina S, Marrazzo F, Migliari M, Stucchi R, Sforza A, Fumagalli R. The response of Milan’s Emergency Medical System to the COVID-19 outbreak in Italy. LANCET 2020 2020-02-28.

11. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 2020-02-07.

12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. LANCET 2020 2020-01-30.

13. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Vol. 23, 2018:130-7.

14. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. LANCET INFECT DIS 2013 2013-09-01;13(9):752-61.

15. Inamura N, Miyashita N, Hasegawa S, et al. Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. Vol. 20, 2014:270-3.

16. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Vol. 9, 1996:1736-42.
Figure legends:

**Figure 1.** Chest computed tomographic images of a 42-year-old patient with refractory COVID-19 pneumonia. Chest computed tomographic images obtained on January 19\(^{th}\) (D0), January 24\(^{th}\) (D5), January 29\(^{th}\) (D10) and February 3\(^{rd}\) (D15). The patient reached remission at day 15.

Table legends:

**Table 1.** Baseline characteristics of patients with refractory COVID-19 pneumonia.

**Table 2.** Laboratory and radiological findings of patients with refractory COVID-19 pneumonia.

**Table 3.** Treatment of patients with refractory COVID-19 pneumonia.

**Table 4.** Multivariate analysis of factors associated with refractory COVID-19 pneumonia.
Table 1. Baseline characteristics of patients with refractory COVID-19 pneumonia.

|                              | Total (n=155) | General (n=70) | Refractory (n=85) | P value |
|------------------------------|---------------|----------------|-------------------|---------|
| Age, median (IQR), years     | 54 (42-66)    | 46 (35-56)     | 61 (51-70)        | <0.001  |
| Male                         | 86 (55.5)     | 31 (44.3)      | 55 (64.7)         | 0.011   |
| Current smoking              | 6 (3.9)       | 2 (2.9)        | 4 (4.7)           | 0.861   |
| Exposure to source transmission | 37 (23.9)     | 16 (22.9)      | 21 (24.7)         | 0.788   |
| Comorbidities, median (IQR), No. | 0 (0-1)      | 0 (0-1)        | 1 (0-1)           | <0.001  |
| Hypertension                 | 37 (23.9)     | 15 (21.4)      | 22 (25.9)         | 0.517   |
| Diabetes                     | 15 (9.7)      | 3 (4.3)        | 12 (14.1)         | 0.039   |
| Cardiovascular diseases      | 15 (9.7)      | 0 (0)          | 14 (16.5)         | 0.002   |
| Cerebrovascular diseases     | 7 (4.5)       | 0 (0)          | 7 (8.2)           | 0.039   |
| Malignancy                   | 7 (4.5)       | 2 (2.9)        | 5 (5.9)           | 0.607   |
| Chronic liver diseases       | 7 (4.5)       | 2 (2.9)        | 5 (5.9)           | 0.607   |
| Chronic renal diseases       | 6 (3.9)       | 2 (2.9)        | 4 (4.7)           | 0.861   |
| COPD                         | 5 (3.2)       | 0 (0)          | 4 (4.7)           | 0.489   |
| Tuberculosis                 | 3 (1.9)       | 0 (0)          | 3 (3.5)           | 0.317   |
| HIV                          | 2 (1.3)       | 0 (0)          | 2 (2.4)           | 0.564   |
| Symptoms and signs           | 3 (2-4)       | 3 (2-4)        | 3 (2-4)           | 0.823   |
| Fever                        | 126 (81.3)    | 63 (90.0)      | 63 (74.1)         | 0.012   |
| Maximum temperature, °C      | 38.5 (38.0-39.0) | 38.3 (38.0-39.0) | 38.8 (38.1-39.2) | 0.005   |
| Cough                        | 97 (62.6)     | 43 (61.4)      | 54 (63.5)         | 0.788   |
| Symptom                        | No. (% of Total) | No. (% of HIV) | No. (% of COVID-19) | P-value |
|--------------------------------|-----------------|---------------|--------------------|---------|
| Chest distress                 | 61 (39.4)       | 22 (31.4)     | 39 (45.9)          | 0.067   |
| Fatigue                        | 60 (73.2)       | 33 (75.0)     | 27 (71.1)          | 0.687   |
| Breath shortness               | 50 (32.3)       | 15 (21.4)     | 35 (41.2)          | 0.009   |
| Myalgia or arthralgia          | 50 (61.0)       | 28 (63.6)     | 22 (57.9)          | 0.595   |
| Anorexia                       | 26 (31.7)       | 8 (18.2)      | 18 (47.4)          | 0.005   |
| Headache                       | 8 (9.8)         | 3 (6.8)       | 5 (13.2)           | 0.554   |
| Diarrhea                       | 7 (4.5)         | 2 (2.9)       | 5 (5.9)            | 0.607   |
| Abdominal pain                 | 3 (1.9)         | 0 (0)         | 2 (2.4)            | >0.999  |
| Nausea                         | 3 (3.7)         | 2 (4.5)       | 0 (0)              | >0.999  |
| Vomiting                       | 3 (3.7)         | 0 (0)         | 2 (5.3)            | 0.897   |
| Chest pain                     | 3 (3.7)         | 2 (4.5)       | 0 (0)              | >0.999  |
| Dizziness                      | 2 (2.4)         | 0 (0)         | 1 (2.6)            | >0.999  |
| Dyspnea                        | 2 (2.4)         | 0 (0)         | 2 (5.3)            | 0.411   |

Severity assessment on admission

| Status | No. (%) | No. (%) | No. (%) | P-value |
|--------|---------|---------|---------|---------|
| Stable | 63 (40.6) | 43 (61.4) | 20 (23.5) |         |
| Serious| 55 (35.5) | 24 (34.3) | 31 (36.5) | <0.001  |
| Critical| 37 (23.9) | 3 (4.3) | 34 (40.0) |         |

IQR, interquartile range; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; COVID-19, coronavirus disease 2019; No., number.
Table 2. Laboratory and radiological findings of patients with refractory COVID-19 pneumonia.

|                                | Normal range | Median (IQR) | P value |
|--------------------------------|--------------|--------------|---------|
| Total (n=155)                  |              |              |         |
| General (n=70)                 |              |              |         |
| Refractory (n=85)              |              |              |         |
| **Blood routine**              |              |              |         |
| White blood cell count, ×10⁹/L | 3.5-9.5      | 4.36 (3.30-6.03) | 4.16 (3.33-5.18) | 4.65 (3.14-6.84) | 0.059     |
| Neutrophil count, ×10⁹/L       | 1.8-6.3      | 2.89 (1.97-4.41) | 2.72 (1.88-3.53) | 3.28 (1.99-5.08) | 0.017     |
| Lymphocyte count, ×10⁹/L       | 1.1-3.2      | 0.90 (0.66-1.11) | 0.97 (0.79-1.28) | 0.80 (0.56-1.04) | 0.105     |
| Platelet count, ×10⁹/L         | 125-350      | 170 (127-208) | 179 (146-219) | 159 (119-202) | 0.049     |
| **Blood biochemistry**         |              |              |         |
| Alanine aminotransferase, U/L  | 9-50         | 23 (16-38)   | 20 (15-33) | 28 (17-42) | 0.545     |
| Aspartate aminotransferase, U/L| 15-40        | 32 (24-48)   | 32 (23-38) | 37 (25-65) | 0.004     |
| Albumin, g/L                   | 40-55        | 38 (34-41)   | 39 (36-42) | 36 (32-40) | 0.001     |
| Globulin, g/L                  | 20-30        | 28 (26-31)   | 29 (26-32) | 28 (26-31) | 0.766     |
| Creatinine, μmol/L             | 64-104       | 71 (60-87)   | 65 (58-78) | 79 (65-96) | 0.158     |
| Lactate dehydrogenase, U/L     | 125-243      | 277 (195-404) | 241 (198-338) | 293 (193-434) | 0.017     |
| Creatine kinase, U/L           | <171         | 93 (60-139)  | 100 (60-146) | 89 (60-140) | 0.560     |
| **Coagulation function**       |              |              |         |
| D-dimer, ng/mL                 | 0-500        | 191 (123-358) | 178 (100-289) | 213 (126-447) | 0.288     |
### Infection-related biomarkers

|                   | Min | 1st Quartile | 3rd Quartile | Mean | Median | P-value |
|-------------------|-----|--------------|--------------|------|--------|---------|
| ESR, mm/h         | 0-15| 25 (14-47)   | 23 (13-41)   | 28 (16-51) | 0.087  |
| C-reactive protein, mg/L | 0-10| 33 (16-74)   | 23 (10-47)   | 46 (22-106) | 0.001  |
| Interleukin-6, pg/mL | 0-7 | 45 (17-96)   | 23 (9-57)    | 64 (31-165) | 0.260  |
| Procalcitonin, ng/mL | <0.05| 0.05 (0.05-0.09) | 0.05 (0.05-0.05) | 0.05 (0.05-0.19) | 0.304  |

### Co-infected respiratory pathogens

| Pathogen                         | na. | Min | 1st Quartile | 3rd Quartile | Mean | Median | P-value |
|----------------------------------|-----|-----|--------------|--------------|------|--------|---------|
| Parainfluenza virus, No. (%)     | na. | 3 (1.9) | 0 (0)       | 2 (2.4)     | >0.99| 9      |
| Syncytial virus, No. (%)         | na. | 3 (1.9) | 0 (0)       | 2 (2.4)     | >0.99| 9      |
| Adenovirus, No. (%)              | na. | 3 (1.9) | 0 (0)       | 3 (3.5)     | 0.317|
| Mycoplasma, No. (%)              | na. | 2 (1.3) | 1 (1.4)     | 1 (1.2)     | >0.99| 9      |
| Influenza virus A, No. (%)       | na. | 2 (1.3) | 0 (0)       | 2 (2.4)     | 0.564|
| Influenza virus B, No. (%)       | na. | 2 (1.3) | 0 (0)       | 2 (2.4)     | 0.564|

### Chest CT or X-ray findings

| Finding                        | na. | Min | 1st Quartile | 3rd Quartile | Mean | Median | P-value |
|--------------------------------|-----|-----|--------------|--------------|------|--------|---------|
| Bilateral distribution, No. (%)| na. | 143 (92.3) | 61 (87.1)   | 82 (96.5)   | 0.031|
| Pleural effusion, No. (%)      | na. | 16 (10.3) | 2 (2.9)     | 14 (16.5)   | 0.006|

IQR, interquartile range; COVID-19, coronavirus disease 2019; ESR, erythrocyte sedimentation rate; na., not available; No., number.
Table 3. Treatment of patients with refractory COVID-19 pneumonia.

|                      | Total (n=155) | General (n=70) | Refractory (n=85) | P value |
|----------------------|---------------|----------------|-------------------|---------|
| Oxygen               | 102 (65.8%)   | 30 (42.9%)     | 72 (84.7%)        | <0.001  |
| Mechanical ventilation| 36 (23.2%)   | 0 (0%)         | 35 (41.2%)        | <0.001  |
| Expectorant          | 87 (56.1%)    | 24 (34.3%)     | 63 (74.1%)        | <0.001  |
| Corticosteroid       | 79 (51.0%)    | 24 (34.3%)     | 55 (64.7%)        | <0.001  |
| Antiviral treatment  | 45 (29.0%)    | 18 (25.7%)     | 27 (31.8%)        | 0.409   |
| Arbidol              | 31 (20.0%)    | 14 (20.0%)     | 17 (20.0%)        | >0.999  |
| Lopinavir and ritonavir | 27 (17.4%) | 6 (8.6%)       | 21 (24.7%)        | 0.008   |
| Interferon inhalation| 30 (19.4%)    | 9 (12.9%)      | 21 (24.7%)        | 0.063   |
| Immune enhancer      | 14 (9.0%)     | 2 (2.9%)       | 12 (14.1%)        | 0.015   |
| Thymalfasin          | 11 (7.1%)     | 0 (0%)         | 11 (12.9%)        | 0.005   |
| Immunoglobulin       | 9 (5.8%)      | 2 (2.9%)       | 7 (8.2%)          | 0.28    |

COVID-19, coronavirus disease 2019; No., number.
Table 4. Multivariate analysis of factors associated with refractory COVID-19 pneumonia.

|                          | B    | SE   | Wals | P value | OR (95% CI)         |
|--------------------------|------|------|------|---------|---------------------|
| Age                      | 0.02 | 0.01 | 2.73 | 0.098   | 1.023 (0.996-1.052) |
| Male                     | 0.79 | 0.40 | 3.96 | 0.047   | 2.206 (1.012-4.809) |
| Comorbidities            | 0.41 | 0.26 | 2.41 | 0.121   | 1.501 (0.899-2.505) |
| Diabetes                 | 0.76 | 0.76 | 1.00 | 0.317   | 2.138 (0.483-9.471) |
| Cardiovascular diseases  | 2.13 | 1.10 | 3.74 | 0.053   | 8.377 (0.973-72.15) |
| Cerebrovascular diseases | 20.21| 13501.26 | 0.00 | 0.999   | na.                 |
| Fever                    | -1.10| 0.53 | 4.26 | 0.039   | 0.331 (0.116-0.945) |
| Maximum temperature      | 0.33 | 0.27 | 1.49 | 0.222   | 1.393 (0.818-2.371) |
| Breath shortness         | -0.42| 0.52 | 0.66 | 0.418   | 0.655 (0.236-1.822) |
| Anorexia                 | 1.37 | 0.63 | 4.72 | 0.030   | 3.921 (1.144-13.443) |
| Blood test               |      |      |      |         |                     |
| Neutrophils              | 0.05 | 0.09 | 0.28 | 0.595   | 1.051 (0.876-1.261) |
| Platelets                | 0.00 | 0.00 | 1.15 | 0.283   | 0.997 (0.992-1.002) |
| Aspartate aminotransferase| 0.00 | 0.01 | 0.00 | 0.972   | 1.000 (0.984-1.0150) |
| Albumin                  | -0.02| 0.04 | 0.33 | 0.565   | 0.980 (0.914-1.050) |
| Lactate dehydrogenase    | 0.00 | 0.00 | 0.95 | 0.331   | 0.998 (0.994-1.002) |
| C-reactive protein       | 0.01 | 0.01 | 2.05 | 0.152   | 1.009 (0.997-1.021) |
| Chest CT or X-ray        |      |      |      |         |                     |
| Bilateral distribution   | 0.07 | 0.77 | 0.01 | 0.925   | 1.074 (0.240-4.817) |
| Pleural effusion         | 1.17 | 0.85 | 1.89 | 0.169   | 3.217 (0.607-17.036) |
| Treatment                |      |      |      |         |                     |
| Oxygen                   | 1.12 | 0.48 | 5.38 | 0.020   | 3.065 (1.189-7.897) |
| Drug                  | OR    | 95% CI Lower | 95% CI Upper | p-Value | Z (Stdev) |
|-----------------------|-------|--------------|--------------|---------|-----------|
| Expectorant           | 0.99  | 0.41         | 5.82         | 0.016   | 2.688     |
| Corticosteroid        | 0.80  | 0.39         | 4.14         | 0.042   | 2.232     |
| Lopinavir and ritonavir | 2.64 | 0.74         | 12.68        | <0.001  | 13.975    |
| Immune enhancer       | 2.19  | 0.84         | 6.80         | 0.009   | 8.959     |
| Thymalfasin           | 21.27 | 10401.18     | 0.00         | 0.998   | na.       |

COVID-19, coronavirus disease 2019; na., not available; OR, odds ratio; CI, confidence interval.
